Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 1289 results for position

  1. Step-by-step guide to registering as a stakeholder

    How to register as a stakeholder with NICE.

  2. How our guidance and standards can help you

    NICE guidance and standards support health professionals by providing evidence-based recommendations that enhance clinical decision-making and patient care.

  3. Use of our content internationally

    Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.

  4. Cost saving, resource planning and audit

    NICE's guidance and advice can help you make the best use of resources and generate cost savings.

  5. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

  6. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

  7. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse (HTG456)

    Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina.

  8. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

  9. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  10. We care about our staff

    We support the wellbeing of our staff in a number of ways including an employee assistance programme, mental health first aiders and a variety of health and wellbeing activities.

  11. EDI roadmap and annual action plan

    NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.

  12. Artificial intelligence (AI) and digital regulations service

    We're playing a leading role in the AI and digital regulations service which supports the development and adoption of AI and data-driven technologies in health and care.

  13. Stage 5: discharge and transferring care

    Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.

  14. Key question: caring

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  15. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.